Figure 14.

The mechanism of action of OMDI in terms of its ability to influence ocular AQH dynamics was studied in lightly anesthetized ocular hypertensive monkeys following ocular dosing with a single drop of 0.002% OMDI. The figure shows that OMDI promoted AQH outflow via both the conventional TM/SC and the uveoscleral outflow pathways (B–D) without altering the production of AQH (A), unlike FP-receptor agonists such as latanoprost that uniquely and primarily activate the uveoscleral pathway (D). Asterisk denotes statistically significant verses the vehicle control.